福泰製藥 VRTX 深 滬
等待開盤 10-30 09:30:00 美东时间
417.21
-5.180
-1.23%
華盛通- 最 高422.98
- 今 開418.02
- 成交量 132.52万股
- 最 低 415.77
- 昨 收 422.39
- 總市值 1068.06亿
- 52周最高 519.68
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 362.50
- 委 比 -71.97%
- 總股本 2.56亿
- 歷史最高 519.88
- 量 比 0.95
- 振 幅 1.71%
- 歷史最低 26.50
- 每 手 1
- 風險率 37.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Veru Announces Proposed Public Offering
Veru Inc. has initiated a public offering of its common stock and warrants, with proceeds intended for the development of enobosarm, particularly the Phase 2b PLATEAU clinical study. The offering is subject to market conditions and includes Series A and B warrants. Veru plans to use the funds for clinical activities, working capital, and collaboration efforts for enobosarm. Canaccord Genuity LLC and Oppenheimer & Co. Inc. are acting as joint book...
10-29 20:01
Vera Bradley Announces Appointment of Melinda Paraie as Chief Brand Officer
Vera Bradley appoints Melinda Paraie as Chief Brand Officer, effective November 1, 2025. Melinda, with extensive experience at Coach and Cath Kidston, will spearhead the company's strategy to revitalize its market position, focusing on product innovation, merchandising, and marketing. Her expertise will help re-engage loyal customers and expand into new markets.
10-29 12:00
Verizon Frontline launches nationwide App Developer Challenge to drive innovation for first responders
Verizon Frontline launches a nationwide app developer challenge to create innovative mobile applications for first responders and public safety agencies. The contest, part of the Verizon Frontline Innovation Program, offers a $25,000 grand prize and分为三阶段：提交、评选和颁奖。参赛者需提交PDF或PPT等文件。入围的三名半决赛选手将受邀参加纽约市的活动，并提供所有旅行住宿。Verizon Frontline致力于通过先进技术和网络提升公共安全专业人员的效率和安全性。更多信息请访问官方网站。
10-28 13:00
Vertex Pharmaceuticals: Pioneering New Treatments for Kidney Disorder
Vertex Pharmaceuticals Inc. (($VRTX)) announced an update on their ongoing clin...
10-28 05:26
嘉实标普生物科技ETF（QDII）三季报解读：净值增长19.51% 净申购4900万份
主要财务指标：本期利润2.52亿元 期末净值15.23亿元 报告期内（2025年7月1日-9月30日），基金主要财务指标表现如下：本期已实现收益5379.2...
10-28 00:03
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Roivant plans to host a live conference call on November 10, 2025, at 8:00 a.m. ET to discuss its Q2 2025 financial results and provide a business update. Registration details and webcast information are available on its website. Roivant is a biopharmaceutical company advancing medicines for various conditions, including autoimmune diseases and pulmonary hypertension, through its "Vants" subsidiaries and health tech initiatives. The press release...
10-27 20:10
VirTra Sets Third Quarter 2025 Conference Call for Monday, November 10, 2025 at 4:30 p.m. ET
VirTra, Inc. (NASDAQ: VTSI), a global provider of judgmental use-of-force and firearms training simulators, will host a conference call on Monday, November 10, 2025 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its third-quarter 2025 financial results. Management will present results, followed by a Q&A session. The call will be available live and for replay via a provided link or the company’s website. U.S. dial-in: 1-877-407-9208...
10-27 12:00
Sanofi higher after Q3 beat driven by Regeneron-partnered Dupixent
Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, whic...
10-24 19:19
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Monte Rosa Therapeutics announced preclinical data for MRT-6160, a molecular glue degrader targeting VAV1, showing potential to treat autoimmune and inflammatory diseases like lupus, Sjögren’s syndrome, and rheumatoid arthritis. MRT-6160 significantly reduced disease markers in a mouse model and outperformed existing therapies. The drug, developed with Novartis, is advancing towards Phase 2 studies, with Monte Rosa eligible for up to $2.1 billion...
10-24 11:00
Adobe weighed $3B purchase of AI startup Synthesia - report
Adobe (NASDAQ:ADBE) explored the acquisition of AI video startup Synthesia in recent months for about $3 billion. Synthesia, a London-based maker of AI software that generates video avatars of people,...
10-23 21:52
